A 177Lu-labeled Inetetamab theranostic conjugate with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy of HER2-positive breast cancer.
PURPOSE HER2-positive breast cancer requires targeted therapies that overcome resistance and desmoplastic barriers. This study aimed to develop and biologically evaluate a 177Lu-labeled Inetetamab conjugate (177Lu-Inetetamab) with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy. METH...